

# Identifying genetic factors underlying osteoporosis and fragility fractures in Malta

Chanelle Cilia<sup>1</sup>, Melissa Marie Formosa<sup>1</sup>, Josanne Vassallo<sup>2</sup> and Angela Xuereb Anastasi<sup>1</sup>


<sup>1</sup>Faculty of Health Sciences, University of Malta, Msida, Malta; <sup>2</sup>Diabetes and Endocrine Centre, Mater Dei Hospital, Msida, Malta



UNIVERSITY OF MALTA  
L-Università ta' Malta



ENDEAVOUR  
SCHOLARSHIPS SCHEME



# Osteoporosis

A complex metabolic bone disease characterised by

- *Reduced bone mineral density*
- *Deterioration of bone microarchitecture*




**Increased risk  
for fracture!**




# ***Fragility fractures***

- Osteoporosis is a '**silent**' & progressive disease
- Affected individuals do not show symptoms until the first fracture occurs



# *Osteoporosis & Fractures in MALTA*



## KEY

- HIGH-RISK\*\*
- Medium-Risk
- Low-Risk


## \*\* *Osteoporosis in Malta*

- 20% of Maltese women
- 6% of Maltese men

## *Fractures in Malta*

- 2,600 fragility fractures sustained in 2010, costing 17 million euro
- 500 hip fractures amounting to 8 million euro
- 68% occurred in women






*Whether peak bone mass is reached*

## Pathophysiology of OP



*Age related bone loss*


*Imbalance in bone remodelling*



# Diagnosis of Osteoporosis

BMD measurement:

**Dual-energy X-ray absorptiometry (DEXA)**



## T-score

Patient BMD compared BMD in healthy young adults matched for gender and ethnic group.

Normal Bone Mass  
(-1.0 and above)

Osteopenia  
(Between -1.0 and -2.5)

Osteoporosis  
(-2.5 and lower)


## Z-score

Patient BMD compared to BMD of healthy normal subject matched for age, gender and ethnic group.

Normal Bone Mass  
(-1.0 and above)

Osteoporosis  
(-2.0 and lower)

# Osteoporosis Risk Factors



# Genetics of Osteoporosis



- OP is a polygenic disease where multiple gene variants each having a small effect contribute to an individual's increased susceptibility to the disease.
- OP has a **strong genetic component**
  - Heritability for BMD 50-85% (Hernandez-de Sosa *et al* (2014) *Calcif Tissue Int.*)
  - Heritability for fracture 25-68% (Michaelsson *et al.* (2005) *Arch Intern Med.*)
- Both **coding** and **low-frequency, non-coding** variants have been identified to be associated with BMD and fracture (Zheng *et al.* (2015) *Nature.*)

# OP Genes Identified by Linkage Analysis ± NGS

Gene. 1998 Aug 17;216(1):103-11.

## **Cloning of a novel member of the low-density lipoprotein receptor family.**

Hey PJ<sup>1</sup>, Twells RC, Phillips MS, Yusuke Nakagawa, Brown SD, Kawaguchi Y, Cox R, Guochun Xie, Dugan V, Hammond H, Metzker ML, Todd JA, Hess JF.

Eur J Hum Genet. 2007 Jul;15(7):800-9. Epub 2007 Mar 21.

## **Linkage to chromosome 11p12 in two Maltese families with a highly penetrant form of osteoporosis.**

Vidal C<sup>1</sup>, Galea R, Brincat M, Anastasi AX.

N Engl J Med. 2013 Oct 17;369(16):1529-36. doi: 10.1056/NEJMoa1308223. Epub 2013 Oct 2.

## **PLS3 mutations in X-linked osteoporosis with fractures.**

van Dijk FS<sup>1</sup>, Zillikens MC, Micha D, Riessland M, Marcelis CL, de Die-Smulders CE, Milbradt J, Franken AA, Harsevoort AJ, Lichtenbelt KD, Prujjs HE, Rubio-Gozalbo ME, Zwertbroek R, Moutaouakil Y, Egthuijsen J, Hammerschmidt M, Bijman R, Semeins CM, Bakker AD, Everts V, Klein-Nulend J, Campos-Obando N, Hofman A, te Meerman GJ, Verkerk AJ, Uitterlinden AG, Maugeri A, Sisternans EA, Waisfisz Q, Meijers-Heijboer H, Wirth B, Simon ME, Pals G.

## **Effects of a synonymous variant in exon 9 of the *CD44* gene on pre-mRNA splicing in a family with osteoporosis**

Christopher Vidal, Adela Cachia, Angela Xuereb-Anastasi  

Edited by: M. Noda




# Study Objectives

*An extended Maltese family having multiple affected members with osteoporosis and/or fragility fractures will be tested.*

1. To identify the causal genes and gene variants in the recruited family, whether known or novel using next-generation sequencing.
2. Shortlisted variants will be replicated in a case-control collection of Maltese post-menopausal women to determine whether the variant affects the BMD and fracture risk at the population level.

# The Research Family



Not affected = not osteoporotic, not osteopenic and no fracture history



Osteoporotic BMD + No fracture history



Osteopenic BMD + No fracture history



Fracture history



Unknown BMD



Proband

# *Recruitment process*

*1. Research Subject  
Consent*



*2. Questionnaire*



*3. Bone Density Scan*




*4. Blood Collection*



# Blood Collection

Collected blood vacutainers are separated




## ***GENETICS***

*To be used for sequencing*

- DNA extraction

*For storage purposes*

- Aliquots
- RNA extraction




## ***BIOCHEMISTRY***

*To exclude 2° conditions*

- Complete Blood Count + differential, ESR
- Folate, Vitamin B12
- Renal profile
- Vitamin D, Calcium, Magnesium
- Coeliac screen
- Hormone profile + Parathyroid Hormone
- Thyroid Function Tests
- Liver Function Tests
- HbA1c, Non-fasting glucose

HIGH MAPPING RATE AND COVERAGE




Bar graph showing the mapping rate and sequencing coverage of the samples using BGISEQ-500 and Illumina HiSeq X Ten platform of 30X WGS.

Table showing comparison of relevant data from BGISEQ-500 and Illumina HiSeq X Ten platforms. As a whole, BGISEQ-500 platform provides comparable results to the Illumina HiSeq X Ten platform.

	BGISEQ-500	HiSeq X Ten
Clean Reads	1001630550	732165210
Clean Bases (Mp)	100163	110083
Mapping Rate	99.47%	96.52%
Unique Rate	94.33%	85.14%
Duplicate Rate	1.77%	11.76%
Mismatch Rate	0.53%	0.56%
Average Sequencing Depth	33.02	31.57
Coverage	99.10%	98.95%
Coverage at least 4X	98.62%	98.43%
Coverage at least 10X	97.68%	97.24%
Coverage at least 20X	93.09%	91.45%



# BGISEQ-500 Project Workflow



# Bioinformatics:

## *Data filtering*

**Data filtering will be performed to generate a list of variants linked to OP and fragility fractures.**

Remove  
common  
variants,  
synonymous  
variants, false  
positive hits.




Variant list will  
be generated.



Variants will be  
filtered using  
*in-silico* tools



Short-listed  
variants



***Known***


- RFLP
- KASP



***Novel***


- Frequency check

# Future studies: Functional work




Testing in population

Association analysis



Functional testing of mutations



Testing of new genes



# Acknowledgments

I would like to thank

- Dr. Melissa Marie Formosa for being not only my tutor, but also providing me with constant help.
- My co-tutor Prof. Angela Xuereb and Prof. Josanne Vassallo.
- Dr. Rosienne Farrugia, Dr. Bezzina Wettinger, Dr. Joseph Borg, Dr. Ritienne Attard and Ms. Francesca Borg-Carabott for their help.
- Dr. Mark Gruppetta for helping me recruit patients.
- My friends and colleagues Dalila Palazzo and Daniel Scerri for their encouragement.



UNIVERSITY OF MALTA  
L-Università ta' Malta



**Thank you for your attention!**